Abstract: In this study, we characterized the first clinical Klebsiella pneumoniae strain coharboring mcr-1 and bla NDM-4 genes in Vietnam, which was recovered from a patient admitted to hospital in 2015. This strain demonstrated nonsusceptible to all tested antibiotics, including last-line antibiotics such as carbapenems (MICs ≥128 μg/mL) and colistin (MIC =32 μg/mL), except tigecycline (MIC =1 μg/mL). Whole-genome analysis using both MinION and MiSeq data revealed that the strain carried 29 resistance genes. Particularly, mcr-1 and bla NDM-4 genes were carried by different self-conjugative plasmids and able to be transferred to a recipient by conjugation. The colistin resistance of this strain was conferred by mcr-1 and additional chromosomal resistance determinants. Eight amino acid substitutions found in PmrA, PmrB, PmrC, PmrI, and PmrJ, all proteins that are involved in lipopolysaccharide modifications, may be associated with chromosomal colistin resistance. The accumulation of multiple antibiotic resistance mechanisms in this clinical isolate raises alarm on potential spread of extensively drug-resistant K. pneumoniae in healthcare settings.
Antimicrobial susceptibility evaluations of K. pneumoniae PI15KP27, recipient E. coli J53Az R and transconjugants were performed by disk diffusion and agar dilution method according to the guidelines of Clinical and Laboratory Standards Institute (CLSI, 2018), except fosfomycin, which was interpreted by the European Union Committee for Antimicrobial Susceptibility Testing (EUCAST, 2019). Minimum inhibitory concentrations (MICs) for colistin and tigecycline were determined by broth microdilution method using guidelines of the EUCAST and the United States Food and Drug Administration (FDA), respectively. The results showed that PI15KP27 was resistant to 23 antibiotics which belonged to 17 classes, including last-resort antibiotics such as carbapenems (MICs ≥128 μg/mL) and colistin (MIC =32 μg/mL). It was intermediate resistance to amikacin (MIC =32 μg/mL) and susceptible to tigecycline (MIC =1 μg/mL) ( Table 1) . The whole-genome sequencing was carried out using the MinION nanopore sequencer (Oxford Nanopore Technologies, UK). Genome assembly was performed by Canu 1.6 4 and then corrected using Pilon 1.22 5 with reads obtained from 250-bp paired-end Illumina MiSeq sequencing (Illumina Inc., USA). Genetic analysis of the complete genome sequence indicated that PI15KP27 consisted of a 5,247,824-bp chromosome with an average 50.1% GC content and three plasmids pKP27-MCR1, pKP27-NDM4 and pKP27-MPH with a sequencing depth of 110. Identification of antimicrobial resistance genes using the ResFinder 3.0 database (https://cge.cbs.dtu.dk/services/ResFinder/) revealed the presence of 29 resistance genes, most of them located on three plasmids (Table 2) . Particularly, the mcr-1 gene was found on a 144,138-bp IncA/C2-type plasmid pKP27-MCR1 and bla-NDM-4 was found on a 121,851-bp IncFIIK-type plasmid pKP27-NDM4, which were able to be transferred into the recipient E. coli strain J53 by conjugation assays. Sodium azide-resistant E. coli J53Az R strain was used as the recipient for the conjugation experiments to examine the transferability of plasmids in the clinical strain. A total of 1ml of each clinical donor and recipient culture was mixed together and incubated at 37°C for 6h. Transconjugants were selected on brain-heart infusion agar (BHIA) (Difco) containing sodium azide (100 μg/mL) plus imipenem (1 μg/ mL), colistin (4 μg/mL), or azithromycin (20 μg/mL). As a result, transconjugants selected on the imipenem supplemented medium or colistin supplemented medium showed antimicrobial susceptibility profiles compatible with resistant phenotypes encoded by genes located on plasmid pKP27-
, bla OXA-9 , aac(6ʹ)-Ib-cr, qnrS1) and pKP27-MCR1 (mcr-1, floR, sul2, tet(A)), respectively ( Table 2 ). In particular, transconjugants selected on imipenem supplemented medium showed resistant to gentamicin, tobramycin, kanamycin, ertapenem, imipenem, meropenem, cefuroxime, cefotaxime, ceftazidime, cefepime, cefoxitin, ampicillin, amoxicillin-clavulanic acid; intermediate to ciprofloxacin and susceptible to trimethoprim-sulfamethoxazole, aztreonam, chloramphenicol, tetracycline, azithromycin, sulfonamides, nitrofurantoin. Transconjugants selected on colistin supplemented medium showed resistant to colistin, chloramphenicol, sulfonamides, tetracycline; intermediate to ampicillin and susceptible to other above remain antibiotics (Table 1 ). There was no strain selected on azithromycin supplemented medium. The presence of mcr-1 and bla NDM4 in the transconjugants was confirmed by PCR. These results illustrated that mcr-1 and bla NDM-4 genes were carried by different self-conjugative plasmids.
There was a significant difference in minimal inhibitory concentration (MIC) for colistin of the clinical strain (MIC =32 μg/mL) in comparison to its transconjugant carrying mcr-1 positive plasmid (MIC =4 μg/mL), indicating that colistin resistance of this strain was conferred by mcr-1 and additional chromosomal resistance determinants. Eight amino acid substitutions were identified by comparison to the genome of K. pneumoniae HS11286 (GenBank accession no. CP003200), including E57G in PmrA; G248R in PmrB; C27F and Q330R in PmrC; I260L in PmrI; V53I, I94L and I300V in PmrJ, all proteins that are involved in lipopolysaccharide modifications, may be associated with colistin resistance. All those mutations, except G248R and Q330R, were earlier observed in some colistin-resistant K. pneumoniae isolates. [6] [7] [8] [9] Further research is required to clarify the significance of these mutations in colistin resistance. The complete sequences of K. pneumoniae strain PI15KP27 and three plasmids have been deposited in GenBank under the accession numbers CP041639-CP041642. The result of multilocus sequence typing (MLST) using MLST1.8 database (https://cge.cbs.dtu.dk/services/ MLST/) indicated that PI15KP27 belonged to sequence type 16 (ST16). This clone has disseminated worldwide with different antimicrobial resistance profiles, which was reported as a β-lactamase producer or involved in outbreaks of CTX-M-15-producing K. pneumoniae.
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Additionally, the ST16 clone was also found in some carbapenem-resistant K. pneumoniae isolates spread in a Abbreviations: GM, gentamicin; AK, amikacin; TOB, tobramycin; K, kanamycin; ETP, ertapenem; IMP, imipenem; MEM, meropenem; CXM, cefuroxime; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; FOX, cefoxitin; CIP, ciprofloxacin; SXT, trimethoprim-sulfamethoxazole; TGC, tigecycline; ATM, aztreonam; AMP, ampicillin; AUG, amoxicillin-clavulanic acid; C, chloramphenicol; FOS, fosfomycine; CS, colistin; TE, tetracycline; AZ, azithromycin; S, sulfonamides; F, nitrofurantoin; NA, not available.
clinical setting in Vietnam. 12 ST16 may become a highrisk clone causing multidrug-resistant hospital-acquired infections. 11 The MLST results in this study support this assumption.
The coexistence of mcr and bla NDM has been commonly identified in E. coli but rarely noted in K. pneumoniae.
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The co-harboring of those genes was reported in K. pneumoniae isolates from both livestock and human clinical samples. 2, 3 To the best of our knowledge, this was the first report in Vietnam of co-production of MCR and NDM in a clinical K. pneumoniae strain. The accumulation of multiple antibiotic resistance mechanisms in this clinical isolate raises alarm on potential spread of extensively drug-resistant K. pneumoniae in healthcare settings. The genomic epidemiology surveillance of hospital-acquired infection pathogens, including colistin-and carbapenem-resistant K. pneumoniae, is highly necessary to prevent their dissemination.
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